TP53 and cancer: Therefore, considering the genomic instability of cancer cells, the emergence of mutations in the DNA binding domain of p53 upon prolonged treatment in vitro with nutlin3a is not surprising (Aziz et al., 2011; Michaelis et al., 2011).